SATIŞ, H. Et Al. 2022. Correspondence on 'Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial'. Annals of the rheumatic diseases , vol.81, no.12 .

SATIŞ, H., AYDEMİR, E., İZMİRLİOĞLU, K., & TUFAN, A., (2022). Correspondence on 'Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial'. Annals of the rheumatic diseases , vol.81, no.12.

SATIŞ, HASAN Et Al. "Correspondence on 'Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial'," Annals of the rheumatic diseases , vol.81, no.12, 2022

SATIŞ, HASAN Et Al. "Correspondence on 'Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial'." Annals of the rheumatic diseases , vol.81, no.12, 2022

SATIŞ, H. Et Al. (2022) . "Correspondence on 'Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial'." Annals of the rheumatic diseases , vol.81, no.12.

@article{article, author={HASAN SATIŞ Et Al. }, title={Correspondence on 'Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial'}, journal={Annals of the rheumatic diseases}, year=2022}